Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Merker

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Neurology|August 17, 2016
Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trialsPamela L Wolters, Staci Martin, Vanessa L Merker, et al.
Clinical Trials (London, England)|December 23, 2023
Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trialsVanessa L Merker, Heather L Thompson, Pamela L Wolters, et al.
Medicine|February 1, 2018
Pain correlates with germline mutation in schwannomatosisJustin T Jordan, Miriam J Smith, James A Walker, et al.
JAMA Internal Medicine|March 3, 2025
Integrating Tobacco Treatment Into Lung Cancer Screening: The Screen Assist Factorial Randomized Clinical TrialElyse R Park, Jennifer S Haas, Nancy A Rigotti, et al.
Neurology|November 4, 2022
Ten-Year Follow-up of Internal Neurofibroma Growth Behavior in Adult Patients With Neurofibromatosis Type 1 Using Whole-Body MRIK Ina Ly, Vanessa L Merker, Wenli Cai, et al.
Neurology|July 7, 2021
Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical TrialsPamela L Wolters, Ana-Maria Vranceanu, Heather L Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2026
Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasJaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Neurology|July 7, 2021
Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical TrialsRaquel D Thalheimer, Vanessa L Merker, K Ina Ly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasJaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
American Journal of Medical Genetics. Part A|October 21, 2016
Creation of an international registry to support discovery in schwannomatosisK L Ostrow, A L Bergner, J Blakeley, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Neurology|August 17, 2016
Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trialsPamela L Wolters, Staci Martin, Vanessa L Merker, et al.
Clinical Trials (London, England)|December 23, 2023
Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trialsVanessa L Merker, Heather L Thompson, Pamela L Wolters, et al.
Medicine|February 1, 2018
Pain correlates with germline mutation in schwannomatosisJustin T Jordan, Miriam J Smith, James A Walker, et al.
JAMA Internal Medicine|March 3, 2025
Integrating Tobacco Treatment Into Lung Cancer Screening: The Screen Assist Factorial Randomized Clinical TrialElyse R Park, Jennifer S Haas, Nancy A Rigotti, et al.
Neurology|November 4, 2022
Ten-Year Follow-up of Internal Neurofibroma Growth Behavior in Adult Patients With Neurofibromatosis Type 1 Using Whole-Body MRIK Ina Ly, Vanessa L Merker, Wenli Cai, et al.
Neurology|July 7, 2021
Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical TrialsPamela L Wolters, Ana-Maria Vranceanu, Heather L Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2026
Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasJaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Neurology|July 7, 2021
Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical TrialsRaquel D Thalheimer, Vanessa L Merker, K Ina Ly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasJaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
American Journal of Medical Genetics. Part A|October 21, 2016
Creation of an international registry to support discovery in schwannomatosisK L Ostrow, A L Bergner, J Blakeley, et al.
Pageof 8